THE LUNG represents a major target for the lodgment of tumour cells following the i.v. tumour-cell challenge or the haematogenous dissemination of tumour cells from a primary tumour site (Baserga et al., 1960; den Brenk, Moore and Sharpington, 1971) . Following the i.v. administration of radiolabelled tumour cells, such cells are preferentially localized within the microcirculation of the lung, where most of them are rapidly destroyed (Fisher and Fisher, 1967; Fidler, 1970; Sadler and Alexander, 1976) . A small percentage of the tumour cells trapped in the lung escape destruction and penetrate into the alveolar spaces and proliferate (Cliffton et al., 1971) .
The growth and proliferation of lung tumour colonies from circulating tumour cells suggests that a critical fraction of these cells is able to escape local tumour surveillance mechanisms.
The role of the reticuloendothelial system (RES) or macrophage system in cellular defence against neoplastic cells is well recognized (Levy and Wheelock, 1974 ). Tumour-cell killing, mediated by non-specifically activated macrophages, has been demonstrated in a variety of in vitro assay systems (Alexander and Evans, 1971; Hibbs, Lambert and Remington, 1972; Keller, 1973) , and is undoubtedly active in the intact host. Many studies have emphasized the importance of inti-mate cell cointact between the macrophage and tumour target cell as a critical prerequisite to the cytotoxic mechanism of the macrophage, in addition to the maintenance of cellular metabolic capacity. An important role for circulating humoral factors has been suggested in the recognition of tumour cells by host macrophages (Di Luzio, 1975; Saba and Antikatzides, 1975) . Alterations in plasma opsonin or humoral recognition-factor activity has been demonstrated in experimental animals and in cancer patients, but its specific relevance to macrophage anti-tumour surveillance mechanisms remains to be determined (Di Luzio, 1975; Aintikatzides, 1975, 1976; Megirian, Saba and Stephenson, 1 976) .
Although the alveolar macrophage is recognized as the major cellular defence mechanism in the lower respiratory tract (Green and Kass, 1964) there are few data oIn the role of mononuclear phagocytes of the lung in defence against lung tumour growth. Pulmonary cellular anti-tumour defence mechanisms may be impaired during the rapid growth of surviving tumour cells in the lung, and this impairment mav be a critical factor allowing for the dissemination and continued local growth of neoplastic cells. The balance between tumour-surveillance mechanisms and tumour-cell load may be critical to the initial development of tumour colonies after tumour challenge, but once established, the growing tumour may feed back and further undermine local defence mechanisms. To illuminate this )roblem, we have studied the functional stability of the alveolar macrophage with respect to phagocytosis, response to an opsonic stimulus, and glucose metabolism, during the growth and spread of lung tumour noduiles. (Saba and Antikatzides, 1975 AM phagocytosis.-Phagocytosis by AM harvested from tumour-challenged or control animals was measured in vitro by the uptake of 14C-labelled Pseudomonas aeroginosa as previously described (Gudewicz et al., 1976a) .
Phagocytosis was initiated by the addition of 2-0 ml of AM suspension (5-10 x 106 AM/ml) in HBSS to 0 5 ml of radiolabelled P. aeruginosa (5-10 x 108 bacteria/ml). Each flask was supplemented with 10% fresh rat serum pooled from either tumour-cell-injected or saline-injected control groups. Flasks were incubated at 37°C in a Dubnoff metabolic shaker bath under room air atmosphere at 60 rev/min for 30 min. Following incubation, AM were collected by centrifugation at 500g for 10 min at 4°C and washed twice in 0-9 00 NaCl to remove non-ingested bacteria. Washed-cell pellets were digested in 0 5 ml of 0-2N NaOH for 4 h at 80°C. The resulting cell digest was cooled to room temperature and neutralized by the addition of 0-1 ml of 500 acetic acid, and duplicate aliquots were added to 10 ml of Scintiverse (Fisher Scientific Co., Rochester, NY). Samples were counted in an Isocap 300 liquid scintillation system (Amersham/Searle Co., Arlington Heights, IL) and phagocytic uptake was expressed as ct/min of 14C-labelled P. aeruginosa/30 min/107 AM.
AM glucose oxidation.-Glucose oxidation via hexose monophosphate shunt (HMPS) was quantified by 14CO2 collection from 1-14C-glucose, using AM as previously described (Gudewicz et al., 1976b) . A suspension of 3-0 ml of AM (2-0 x 107 AM/ml) in HBSS was added to metabolic flasks containing 5-5 mM glucose, 12-5% fresh rat serum and 0-5 ,uCi of 1-14C-glucose (New England Nuclear, Boston, MA) with a total final volume of 5-0 ml. Comparisons were made between cells obtained from control and tumourbearing rats when incubated in serum obtained from the various groups. Flasks were incubated with or without heat-killed P.
aeruginosa (bacteria: macrophage ratio = 10: 1) for 60 min at 37°C, and the reaction was terminated by the addition of 1-0 ml of 6N H2804. At termination, the flasks were incubated for an additional 15 min, and the 14CO2 evolved was trapped in scintillation vials on filter paper containing 0-3 ml of hyamine hydroxide. A volume of 1-5 ml of 040o 1,5-diphenyl-oxazole and 0-01% 1,4-bis [2(5-phenyl-oxazoly')]benzene in toluene was added and the vials -were counted in the liquid scintillation system. Counting efficiency was 65-700o and the activity was expressed as ct/min of 14CO2 evolved/60 min/107 AM.
RES ULTS
The temporal development of macroscopic lung tumour nodules in response to i.v. tumour-cell challenge is illustrated in Table I . Macroscopic lung tumour week, possibly representing a response to the proliferation of lung tumour colonies. Cell viability was greater than 95% at all intervals measured (cell differentials of lavage fluid from tumourchallenged groups revealed a predominantly mononuclear macrophage cell population). Tumour cells were excluded from all lung-lavage cell counts of macrophage yields.
In vitro phagocytic activity of lung macrophages one week after i.v. tumourcell challenge is presented in Table III bearing rats had the least phagocytic activity.
In an attempt to determine whether specific aspects of macrophage energy metabolism were altered prior to or during the decline in phagocytic capacity observed with lung-tumour growth, glucose oxidation by alveolar macrophages was examined in vitro in the absence or presence of bacterial phagocytosis. The Figure illustrates the 14CO2 production from 1-14C-glucose by AM harvested prior to and at one and three weeks after i.v. tumour challenge. Macrophage oxidation of 1-14C-glucose was markedly depressed, with non-phagocytizing cells as well as during bacterial phagocytosis, when the macrophages studied were harvested one week after tumour challenge. The depression of glucose oxidation by AM was significant (P < 0 001) and persisted 3 weeks after tumour-cell injection. glucose oxidation during phagocytosis was only 24% in the presence of serum from tumour-challenged groups, which was -500/ less than that seen in controls. In contrast, AM from lung-tumour-bearing animals showed a significant depression in glucose oxidation relative to control AM. This was consistently observed with or without associated bacterial phagocytosis, although the response to bacterial challenge was evident.
DISCUSSION
Non-specific stimulation of the reticuloendothelial system (RES) enhances host resistance to tumour growth and tumourcell dissemination (Stern, 1960; Old et al., 1961; Hanna, Zbar and Rapp, 1972) while macrophage dysfunction has been correlated with impaired anti-tumour immunity (Kampschmidt and Clabaugh, 1964; Saba and Antikatzides, 1976) . The neoplastic process itself has a deleterious effect on RES function (Franchi et al., 1972; Di Luzio, 1975; Saba and Antikatzides, 1975) clearly indicating that the suppression of the macrophage, or inability of the macrophage to become activated, may be a critical event in the dissemination and proliferation of neoplastic cells. Thus, while compromised macrophage function may be aetiologic in the development of cancers, the growth and spread of malignant disease may feedback and undermine macrophage antitumour activity and set in motion a positive feedback cycle leading to host deterioration.
In contrast to abundant studies correlating stimulation of systemic RE function with increased tumour-cell killing, the influence of tumour growth on local pulmonary alveolar macrophage function is not well documented. Modification of innate lung defence mechanisms can influence the extent of lung-tumour growth from blood-borne tumour cells. For example, pulmonary metastatic tumour growth from i.v. injected tumour cells can be enhanced by local X-irradiation of the lung (van den Brenk et al., 1973; surgically induced hepatic RE depression (Saba and Antikatzides, 1976; van den Brenk et al., 1976) pharmacologically induced pulmonary inflammatory reactions or i.v. injection of potent cytostatic agents such as cyclophosphamide (van Putten et al., 1975; Carmel and Brown, 1977) . Although the mechanisms accelerating lung-tumour growth after pulmonary injury are not understood, such a response may be mediated by an escape from non-specific tumour-surveillance mechanisms.
The initial host-defence response of the pulmonary RES to tumour-cell challenge appeared to be macrophage proliferation, with no change in phagocytic activity. However, the appearance of macroscopic lung tumour nodules was subsequently associated with depression of AM activity. Optimal bacterial phagocytosis by AM appears dependent upon humoral opsonic factors (Reynolds, Kazmierowski and Newball, 1975) and the maintenance of glucose metabolism for the provision of metabolic energy (Ouchi, Selvaraj and Sbarra, 1965 (Gee et al., 1974) and increased transport of glucose to provide an energy substrate (Bonventre and Mukkada, 1974; Gudewicz et al., 1976b Pike and Snyderman (1976) of depressed macrophage chemotactic behaviour under the influence of a lowmol.-wt heat-stable inhibitory factor isolated from growing tumours in mice, lend credence to this concept. The present findings of increased macrophage content of the alveolar space and altered macrophage physiological behaviour with tumour growth, must be considered with respect to the data of Eccles, Bandlow and Alexander (1976) and Eccles and Alexanider (1974) . They observed increased macrophage content of growing tumours, which was related to the degree of immunogenicity of the tumour, and a parallel impairment of monocyte ability to enter a site of inflammation. Tumour growth following transplantation, as investigated in rats with 2 svugenieic transplanted sarcomas, elicited a distinct monocytosis which declined after surgical removal of the tumour (Eccles et al., 1976) . They proposed that states of "immunological anergy" with tumour growth may be related to the lack of availability and participation of macrophages in the inflammatory response, although the mechanism remains to be defined. Such findings demonstrate another a,spect of altered macrophage function that can result from tumour growth.
Thus, the success of circulating tumour cells or actively growing neoplasms to undermine macrophage activities, may be a significant neoplasm-induced local escape mechanism which can compromise antitumour host defence mechanisms. When viewed with this perspective, surgical removal of the neoplasm may provide both an indirect and direct approach to the limitations of tumour growth and spread. Wlhen coupled with suipportive immunotherapy to activate local macrophages and specific immune mechanisms (McKneally, Maver and Kausel, 1976) significant success may be achieved in dealing with some lung tumours. Indeed, some forms of immunotherapy administered locally after lung-tumour resection (McKneally et al., 1976) may actively augment macrophage function, reversing the negative effect of tumour growth.
